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Background: The proprotein convertase subtilisin/kexin type 9 (PCSK9) has been confirmed as a major factor
regulating cholesterol homeostasis and has low-density lipoprotein receptor (LDLR) independent effects. In addition,
the pathogenesis of acute myocardial infarction (AMI) involves lipids alteration and other acute phase responses. It
remains unknown whether the PCSK9 expression is influenced by the impact of AMI. The present study aimed to
investigate the changes of PCSK9 concentration using AMI rat model.
Methods: AMI (n = 6-8 at each time point) or sham operated (n = 6) adult male rats model were used. Whole
blood and liver tissue were collected at 1, 3, 6, 9, 12, 24, 48, and 96 hour (h) post infarction. The plasma PCSK9
concentration was measured by ELISA and lipid profiles were measured by enzymatic assay. The liver mRNA levels
of PCSK9, LDLR, sterol response element binding protein-2 (SREBP-2) and hepatocyte nuclear factor 1α (HNF1α)
were measured by quantitative real-time PCR.
Results: The plasma PCSK9 concentration was increased from 12 h to 96 h (P < 0.05 vs. control). Paralleled with the
enhanced plasma PCSK9 concentration, the hepatic PCSK9 mRNA expression was up-regulated by 2.2-fold at 12 h
and 4.1-fold at 24 h. Hepatic mRNA levels of LDLR, SREBP-2 and HNF1α were all increased and lipid profiles underwent
great changes at this acute period.
Conclusions: We firstly demonstrated that PCSK9 was transiently up-regulated in the acute period of AMI, which is also
driven by transcriptional factors, SREBP-2 and HNF1α, suggesting that the role of PCSK9 in myocardial injury may be
needed further study.
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Proprotein convertase subtilisin/kexin type 9 (PCSK9), ori-
ginally discovered as a third gene involved in autosomal
dominant hypercholesterolemia [1], has gained consider-
able attention over the past decade. A number of studies
have demonstrated that, a high level of plasma PCSK9,
caused by gain-of-function mutations in human or
over-expression in animal model, exclusively resulted in
increased serum concentration of low-density lipoprotein-
cholesterol (LDL-C), and that the patients with gain-of-* Correspondence: tangyue1226@vip.sina.com; lijianjun938@126.com
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unless otherwise stated.function mutations presented with increased cardiovascular
risk [2-5]. Conversely, loss-of-function mutations in PCSK9
and knockdown of PCSK9 gene caused not only a low
plasma level of PCSK9, but also a significant decreased level
of LDL-C, accompanied by decreased cardiovascular risk
[5,6]. Recent studies have elucidated that PCSK9 is mainly
synthesized by the liver and has been shown to bind to the
low-density lipoprotein receptor (LDLR), subsequently pro-
moting its degradation [7]. This process reduces the avail-
ability of LDLR, the major receptor mediating the clearance
of low-density lipoprotein (LDL) particle, and results in in-
creased plasma LDL-C levels. Since elevated LDL-C has
long been established as a predominant risk factor for cor-
onary artery disease (CAD), manipulating PCSK9 level
would be a promising new treatment strategy [8].This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Sequence of primers used in real-time RT-PCR






PCSK9 = proprotein convertases subtilisin kexin 9; LDLR = low-density
lipoprotein receptor; SREBP-2 = sterol response element binding protein-2;
HNF1α = hepatocytenuclear factor 1α; GAPDH = glyceraldehyde-3-phosphate
dehydrogenase.
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http://www.biomedcentral.com/1471-2261/14/192The pathogenesis of acute myocardial infarction (AMI) is
multifactorial, however, several studies have indicated that
hyperlipidemia is a major risk factor accountable for 54% of
population-attributable risk for AMI [9]. In addition, previ-
ous studies have reported that during the acute stage of
AMI, serum lipids metabolism was severely affected [10].
Whereas PCSK9, an important factor regulating cholesterol
homeostasis, has been reported to be associated with a var-
iety of physiological and pathological factors dependent or
independent of the LDLR, such as statins [11], fenofibrate
[12], fasting [13], sex [14], periodontal infection [15], sys-
temic inflammation [16], severe trauma injury [17] and the
severity of coronary atherosclerosis [18]. However, it re-
mains unknown whether the PCSK9 expression is influ-
enced by the impact of AMI. Therefore, the aim of present
study was to investigate the changes of both plasma and
liver PCSK9 level using the AMI rat model.
Methods
Animal model
Adult male Sprague–Dawley rats (n = 6-8 at each time
point), weighing 260-280 g, were acclimatized with a
12 hour (h) light/dark cycle at a controlled room tem-
perature of 22–24°C, and rats were allowed free access
to the regular and normal diet (fat content 4.62%) and
clean drinking water for seven days before use. Myocar-
dial infarction models were induced by ligation of the
left anterior descending coronary artery (LAD) under
ether anesthesia as previously described [19]. Electrocar-
diography was used to demonstrate ST elevation and
thereby confirm the success of surgery. Sham operated
animals (n = 6) underwent the same procedure except
that no ligation was carried out. The experimental pro-
cedures were approved by the Institutional Animal Care
and Use Committee of the FuWai Hospital and conformed
to Guide for the Care and Use of Laboratory Animals
from National Institutes of Health.
Blood and tissue sampling
Prior to sacrifice, 2 mL fasting blood samples were col-
lected from the tail vein at 1, 3, 6, 9, 12, 24, 48, and 96 h
post infarction and transferred to K2 EDTA tubes. The
blood samples were centrifuged, and the plasma was
stored at −80°C until the analyses were performed. Im-
mediately after blood sampling, the animals were sacri-
ficed by an overdose of pentobarbital sodium. Tissue
fragments from liver were collected and snap-frozen in
liquid nitrogen and stored at −80°C.
Blood sample measurements
Concentrations of serum total cholesterol (TC), triglycer-
ides (TG), high-density lipoprotein-cholesterol (HDL-C),
LDL-C, and free fatty acid (FFA) were determined on an
automatic biochemistry analyzer (Hitachi 7150, Tokyo,Japan). Plasma PCSK9 concentration was measured using
a high-sensitivity, quantitative sandwich enzyme im-
munoassay (Quantikine ELISA, R&D Systems Europe Ltd)
according to our previous studies [20]. The lower limit
of detection was 0.096 ng/ml. The white blood cell
counts (WBCC) were determined using an automated
blood cell counter (Beckman Coulter Ireland Inc Mervue,
Galway, Ireland).
RNA isolation, cDNA synthesis and quantitative
real-time PCR
Following the manufacturer’s instructions, the total RNA
of liver tissue was isolated using the Trizol reagent
Kit (Invitrogen, USA) with the aid of an Omni Tissue
Homogenizer, and then was measured by spectrophotom-
etry at an absorbance of 260 nm, and designated the purity
valid if the ratio of A260/A280 was in the range of 1.8 to
2.0. The integrity of the RNA was checked by denaturing
agarose gel electrophoresis and ethidium bromide staining.
First-strand cDNA was synthesized from 2 μg of total RNA
using revert Aid First Strand cDNA synthesis kit (Promega,
USA). Sequences of primers were given in Table 1. The
abundances of key genes (PCSK9, LDLR, sterol regulator
element binding protein-2 (SREBP-2), hepatocyte nuclear
factor 1α (HNF1α)) and glyceraldehyde-3-phosphate de-
hydrogenase (GAPDH) mRNA were analyzed by real time
quantitative PCR (RT-PCR). RT-PCR reaction was carried
out with SYBR Premix ExTaq (TaKaRa Bio Inc. Japan) on
7500HT RT-PCR system (Applied Biosystems, Foster, CA,
USA). Standard curves for each primer pair were generated
by serial dilutions of cDNA from a reference sample and
used for regression analyses. All PCR assays were per-
formed in triplicate. The variance of the triplicate measure-
ments was < 1%. Results were analyzed using the standard
curve method by the sequence detection systems (SDS)
software. All results were normalized against GAPDH.
Statistical analysis
Continuous variables were expressed as mean ± standard
deviation (SD). One-way analysis of variance (ANOVA)
followed by the Dunnett’s T3 test (unequal variances) or
Bonferroni test (equal variances) were performed to test
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less than 0.05 was considered statistical significance. The
SPSS 19.0 statistical software package (SPSS Inc., Chicago,
IL, USA) was used for all of the statistical analysis.
Results
Plasma concentration of PCSK9 and WBCC
The plasma concentration of PCSK9 in sham and AMI
groups were indicated in Figure 1. Compared with sham
group, PCSK9 concentration was significantly increasedFigure 1 Plasma levels of PCSK9 (A), FFA (B), TG (C), TC (D), LDL-C (E), an
proprotein convertase subtilisin/kexin type 9; FFA = free fatty acid; TG = triglyc
HDL-C = high-density lipoprotein-cholesterol.at 12 h (544.18 ± 262.69 ng/ml vs. 293.53 ± 119.90 ng/ml,
P < 0.05 vs. control) post AMI, and reached a peak level
of 1647.29 ± 120.47 ng/ml (P < 0.05 vs. control) at 48 h,
then decreased thereafter to reach a value of 467.54 ±
155.73 ng/ml (P < 0.05 vs. control) at 96 h. Meanwhile, we
observed that the plasma WBCC level was increased at
3 h after infarction (6.32 × 109/L vs. 4.24 ± 1.32 × 109/L in
sham group, P < 0.05 vs. control), and continued to rise at
6 h and 12 h (9.58 ± 2.26 × 109/L, 12.74 ± 3.88 × 109/L, re-
spectively; both P < 0.05 vs. control).d HDL-C (F) in sham and AMI groups. *P < 0.05 vs. control. PCSK9 =
eride; TC = total cholesterol; LDL-C = low-density lipoprotein-cholesterol;
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FFA level started to increase at 3 h after AMI, and main-
tained a high level until 24 h, then decreased to a level
similar to that of the sham group. There was no signifi-
cant change in TG level from 1 h to 96 h even though it
showed a decrease and then regressive trend. The TC
level exhibited an increase at 3 h after AMI, and there-
after maintained a high level with intermediate fluctua-
tions at 6 h and 24 h. Its concentration returned to the
sham level at 96 h. There was no significant change in
LDL-C level from 1 h to 96 h except for two transient
increase of LDL-C at 12 h and 48 h. HDL-C level was
steady at most of the time point except for two transient
increase at 3 h and 48 h.Expression of PCSK9 and LDLR mRNA in AMI rat
hepatic cells
To determine the relative mRNA expression of PCSK9
and LDLR in the liver at different time post AMI, RT-
PCR was performed. As shown in Figure 2A-B, at 12 h
and 24 h, the amount of PCSK9 mRNA was increased
by 2.2-fold and 4.1-fold, respectively (P < 0.05 vs. control),
then followed by a precipitous drop to a level similar to
that of the sham group at 48 h and 96 h. Expression of the
LDLR mRNA, which is known to be associated with
PCSK9, was also increased by 4.7-fold at 12 h, and reached
a peak level at 24 h (increased by 6.7-fold), but slightly de-
creased to 4.4-fold at 48 h (P < 0.05 vs. control). At 96 h,Figure 2 The mRNA expression of PCSK9 (A), LDLR (B), SREBP-2 (C) a
The relative ratio and standard deviation were calculated using comparat
GAPDH. *P < 0.05 vs. control. PCSK9 = proprotein convertase subtilisin/kexi
regulator element–binding protein-2; HNF1α = hepatocyte nuclear factor 1there existed no significant difference compared to the
sham group.Expression of SREBP-2 and HNF1α mRNA in AMI rat
hepatic cells
To determine the transcriptional level mechanism under-
lying the mRNA alteration of PCSK9 and LDLR at differ-
ent period of AMI, we quantified SREBP-2 and HNF1α
expression using RT-PCR. The mRNA expression of
SREBP-2 (Figure 2C) and HNF1α (Figure 2D) were both
up-regulated at 12 h (1.9-fold and 6.5-fold, respectively,
P < 0.05 vs. control) and reached their peak level at 24 h
(2.8-fold and 6.9-fold, respectively, P < 0.05 vs. control),
then dropped to the level similar to the sham group since
48 h.Discussion
PCSK9 has been confirmed as a major factor regulating
hepatic LDLR proteins and consequently serum choles-
terol levels [7]. Recently, several studies have empha-
sized that PCSK9 was also involved in the physiology
of non-hepatic cells or have LDLR-independent effects
[15,16]. Interestingly, in the present study our data for
the first time found that the plasma PCSK9 concentra-
tion was drastically induced from 12 h to 96 h at the
acute period of AMI in rat model. Paralleled with the
enhanced plasma PCSK9 concentration, hepatic PCSK9
mRNA expression was also up-regulated by 2.2-fold atnd HNF1α (D) in the liver were measured using real-time PCR.
ive CT method (ΔΔCT value). All results were normalized against
n type 9; LDLR = low-density lipoprotein receptor; SREBP-2 = sterol
α; GAPDH = glyceraldehyde 3-phosphate dehydrogenase.
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studies, the up-regulated PCSK9 expression could be
driven by SREBP-2 [21] and HNF1α [22], both of which
are pivotal transcription factors for PCSK9.
The mechanisms accounting for the transiently up-
regulated PCSK9 level at the acute period of AMI re-
main unclear. We speculated that it may be correlated
with the following factors. Primarily, systemic inflamma-
tion may be one of the involving mechanisms. Inflam-
mation is a hallmark throughout the distinct stages
of atherosclerotic lesion formation preceding AMI as
well as the time of plaque rupture [23]. Several large,
prospective epidemiological, clinical and experimental
studies converge on inflammation as a pivotal factor
in AMI progression and exacerbation [24,25]. In the
study conducted by Yavuz MT et al. demonstrated that
patients with significant coronary stenosis had elevated
interleukin-6 (IL-6), high-sensitivity C-reactive protein
(hs-CRP) and higher WBCC levels [26]. In the current
study, we also observed that the plasma level of WBCC
was dramatically increased at the early stage of AMI. Our
previous clinical studies [27,28] showed that a per-
sistent and enhanced inflammatory responsiveness to
pro-inflammatory stimulators, such as C-reactive protein,
are involved in the pathogenesis of acute coronary syn-
drome. In a study neutrophil to lymphocyte ratio (NLR)
was found to have a significant relationship with the se-
verity of ACS assessed by SYNTAX Score and higher
NLR was found in ST elevation myocardial infarction pa-
tients [29]. Activated neutrophils release a variety of pro-
teolytic enzymes such as myeloperoxidase, which are
responsible for tissue injury [30]. Therefore, it has been
well established that the pathogenesis of AMI is accom-
panied with systemic inflammation. Additionally, the
study conducted by Feingold KR et al. [16] demonstrated
that in mice systemic inflammation induced by lipopoly-
saccharide or other treatments all resulted in a marked
increase in hepatic PCSK9 mRNA levels (4 h-2.5 fold in-
crease; 38 h-12.5 fold increase). Thus, it seems reason-
able to consider inflammation as one of the underlying
mechanisms. The second mechanism may be associated
with the injury induced by AMI. Le Bras M et al. [17] re-
vealed that plasma PCSK9 level was increased by 2-fold
between days 0 and 8 in patients with severe multiple
trauma, which may provide evidence that injury may be
involved in the up-regulation of PCSK9 during the acute
phase of AMI. Finally, necrosis and apoptosis [31] in the
process of AMI may be the additional mechanism for the
increased PCSK9 concentration. Similar to our study,
Rousselet E et al. demonstrated that ischemic stroke trig-
gered an up-regulation of PCSK9 level [32]. Additionally,
Wu CY et al. using human endothelial cells demon-
strated that oxidized LDL-induced apoptosis resulted ele-
vated expression of PCSK9 and the apoptosis could beinhibited by PCSK9 siRNA [33]. It is plausible to consider
that the above factors may contribute to the up-regulated
PCSK9 level. However, detailed studies are warranted to
explore the exact mechanisms involved in this specific
pathological condition.
Although clinical implications of the elevated plasma
PCSK9 concentration in the acute period of AMI are
still vague, there may be several clinical significances.
Firstly, PCSK9 may be an acute-phase response protein
(APRP). In our study, we found that plasma PCSK9 con-
centration was remarkably induced from 12 h to 96 h
post AMI. The impact of the increased PCSK9 concen-
tration may be correlated to elevated serum LDL-C
levels, which could have beneficial effects on host
defense [34]. The changing pattern and relating impact
of PCSK9 may be in accordance with standard APRP.
However, Le Bras M et al. [17] showed that in patients
with severe multiple trauma were lack of a rapid in-
crease of circulating PCSK9 level, and posed a challenge
to the hypothesis that PCSK9 is an APRP. Thereby,
more investigations are required to verify this hypoth-
esis. Secondly, PCSK9 may be a biomarker for future
events of AMI. Previous study had demonstrated that at
day 8, plasma PCSK9 concentrations were positively as-
sociated with clinical severity and acted as a late bio-
marker of severity illness in the severe trauma patients
hospitalized in the intensive care unit [17]. Besides that,
PCSK9 has been demonstrated to be expressed in hu-
man atherosclerotic plaques [35] and the study inves-
tigated the relationship between PCSK9 genotypes/
haplotypes and severity of coronary atherosclerosis
elucidated a modest association between minimum
lumen diameter tertiles and haplotype 3 [18]. Based
on these findings, we tentatively speculated that
plasma PCSK9 concentration may be related to the
infarct size and severity, which were predicting fac-
tors for cardiac remodeling [36] and even cardiac
dysfunction. As a result, we suspected that PCSK9
may be a biomarker for the prognosis of AMI.
Nevertheless, such hypothesis is being of under in-
vestigation in our group. Thirdly, the intensive statin
therapy is an essential strategy after AMI [37]. Early
administrated with statin can improve the outcome
in those patients [38]. Considering the up-regulated
PCSK9 expression by statin and AMI, adding PCSK9
inhibitors may bring greater benefits for those pa-
tients. Such hypothesis is also needed to be con-
firmed in the future.
Our study has several limitations. First, we did not ob-
serve the long-term impact of the enhanced PCSK9 ex-
pression on the prognosis parameters in the AMI rat
model. Second, we did not evaluate the protein levels of
PCSK9 and LDLR, which may provide more evidence
about the relationship between PCSK9 and LDLR.
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In summary, we demonstrated for the first time that
plasma PCSK9 concentration was significantly induced
at 12 h after AMI, and still higher than the sham group
at 96 h, and this result was further confirmed by the in-
creased liver mRNA levels. At the transcriptional level,
SREBP-2 and HNF1α were the predominate factors that
activated the expression of PCSK9. The role of PCSK9
in myocardial injury may be needed further study.
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